Skip to main content
. 2014 Dec 8;9(2):739–744. doi: 10.3892/ol.2014.2779

Figure 3.

Figure 3

3-Bromopyruvate (3-BrPA) inhibits B-cell lymphoma 2 (Bcl-2) expression and promotes Bcl-2-associated X protein (Bax) expression. Representative immunoblots revealing the expression of (A) Bcl-2 and (B) Bax in the (a) NS, (b) 3-BrPA low-dose, (c) 3-BrPA medium-dose, (d) 3-BrPA high-dose and (e) 5-fluorouracil groups. Treatment with 3-BrPA decreased Bcl-2 expression and increased Bax expression in a dose-dependant manner.